Ocular in-situ gel preparatino with proper phase conversion temperature

A phase transition temperature, in-situ gel technology, which is used in medical preparations with non-active ingredients, sensory diseases, drug combinations, etc., to achieve the effects of improving local bioavailability, delaying drug elimination, and facilitating medication

Inactive Publication Date: 2002-11-06
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 110 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Based on all the retrieved literature, it has not been reported that different types of poloxamers are

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ocular in-situ gel preparatino with proper phase conversion temperature
  • Ocular in-situ gel preparatino with proper phase conversion temperature
  • Ocular in-situ gel preparatino with proper phase conversion temperature

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Timolol maleate ophthalmic in situ gel; take timolol maleate 0.25%, brogeramine 0.02%, 21% poloxamer 407, 10% poloxamer 188, sterile isotonic Phosphate buffer solution (pH7.4) to full volume. The drug and benzalkonium chloride are dissolved in water, and the poloxamer is slowly added to the above solution under ice bath and stirring conditions, and stored under low temperature refrigeration until a clear solution is formed.

Embodiment 2

[0033]Ofloxacin ophthalmic in situ gel with hyaluronic acid; take ofloxacin 0.3%, sodium hyaluronate 0.2%, 21% poloxamer 407, 10% poloxamer 188, sterile Isotonic phosphate buffer solution (pH7.4) to full volume. Sodium hyaluronate was dissolved in the buffer solution, and then ofloxacin ophthalmic in situ gel was prepared according to the process of Example 1.

Embodiment 3

[0035] Acyclovir Ophthalmic In Situ Gel Containing Carbomer; Take Acyclovir 2%, Brogeramine 0.02%, Carbomer 934P 0.2%, Mannitol 5%, Poloxamer 407 22%, 10 % Poloxamer 188, sterile water to full volume. Disperse carbomer in water, adjust the pH to neutral with sodium hydroxide solution, add drugs, benzalkonium chloride and mannitol, slowly add poloxamer to the above solution under ice bath and stirring conditions, and store in low temperature refrigeration until a clear solution is formed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The gel preparation has the merits of both solution and gel. By means of the combination of different type poloxamers, ocular in-situ gel preparation containing medicine and water soluble polymer supplementary material is prepared. The preparation contains poloxamer 407 and poloxament 188 as well as water soluble polymer supplementary material less than 3%. The preparation has proper phase conversion temperatur and may form gel on the surface of cornea of living body after being applied in liquid state at room temperature. The present invention can delay the disappearance of medicine and raise the biological utilization in some local area and is suitable for various ocular medicines.

Description

Technical field: [0001] The invention relates to a novel dosage form of ophthalmic medicine-an ophthalmic in-situ gel preparation with a suitable phase transition temperature. Specifically, it is a temperature-sensitive polymer aqueous solution, which is in a liquid state at room temperature, and quickly forms a gel on the corneal surface after administration in the form of eye drops, thereby delaying drug elimination and improving local bioavailability. Background technique: [0002] Many eye diseases, such as glaucoma, corneal infection and inflammation, etc., will eventually lead to serious consequences of blindness if they are not treated in time and effectively. The use of appropriate drugs can effectively control the disease, relieve or eradicate symptoms, and choosing a reasonable dosage form to ensure the safety and effectiveness of the drug and make the patient willing to accept it is an important issue in drug treatment. [0003] According to statistics, solution-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61K47/10A61K47/36A61P27/02
Inventor 魏刚郑俊民
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap